Psychedelics Cybin receives FDA approval for new in-human clinical trial Patient enlistment for new study to treat Major Depressive Disorder set to begin promptly Rowan Dunne3 days ago
Coming soon PAREA: A new psychedelic-focused alliance of prominent companies with common goals Multi-organization psychedelic partnership set to launch on June 23 Rowan DunneJune 16, 2022
Business Entheon Biomedical hands off DMT clinical study to Cybin Dimethyltryptamine continues to demonstrate tremendous therapeutic potential Rowan DunneJune 14, 2022
Culture Numinus announces Music as Medicine event series Series of concerts across the U.S. and Canada will explore music’s role in psychedelic-assisted therapy Ryan GarnerMay 3, 2022
Business Numinus ups revenue 61% thanks to psychedelic-focused therapy programs Expenses were down 71% but the firm still reported a $5.4-million loss Natalia Buendia CalvilloJanuary 21, 2022
Industry update MagicMed attracts investors to advance library of psychedelic derivatives After raising $8.1M, the Calgary company filed 12 patents and launched a candidate selection program for novel psychedelic mental health treatments Jared GnamDecember 23, 2020
Investment Ideas MagicMed aims to mainstream psychedelic therapy with world’s largest ‘Psybrary’ Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine Jared GnamDecember 1, 2020
Psychedelics Psilocybin therapy 4 times more effective than antidepressants: study A first-of-its-kind clinical trial shows a dramatic drop in depression in over half of patients who received a synthetic version of the compound Jared GnamNovember 6, 2020
The weed wire UC Berkeley’s new psychedelic research centre wants to change your mind The new hub will focus on the rapidly advancing field by adding unique public education and spiritual components Jared GnamSeptember 16, 2020
The weed wire Mushroom company Mydecine acquires veteran-focused psychedelic firm With deep Canadian and U.S. military ties, NeuroPharm Inc. is about to launch psychedelic-based clinical trials Jared GnamJuly 15, 2020